Technology-driven gene therapy CDMO from oligonucleotide to xRNA
Location: South Korea, Seoul
Employees: 51-200
Founded date: 1983
Investors 2
| Date | Name | Website |
| 18.05.2023 | Synergy IB... | synergyib.... |
| - | E&Inve... | eninvestme... |
Mentions in press and media 4
| Date | Title | Description |
| 21.11.2023 | ST Pharm Presented '100-Day Expedite Strategy', Preparedness and Proactive Measures for Future Pandemic at Korea-CEPI R&D Workshop | SEOUL, South Korea, Nov. 21, 2023 /PRNewswire/ -- Nov. 21, 2023 local time, ST Pharm announced 'Rapid Preparedness of Pandemic Vaccine in 100 Days using ST Pharm's own mRNA Platform Technology' at the Korea-CEPI R&D Workshop in World Bi... |
| 19.09.2023 | ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility | SEOUL, South Korea, Sept. 19, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities. Th... |
| 03.08.2022 | ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022 | - STP0404 is the only clinical safety proven HIV treatment candidate with a novel mechanism that can block HIV re-activation. - STP0404 is expected to enter Phase 2a clinical trial in the US in 4Q 2022. SEOUL, South Korea, Aug. 3, 2022 /PRN... |
| 29.11.2021 | ST Pharm announces expansion of oligonucleotide facility, taking a leap towards the world's largest oligonucleotide CDMO | SEOUL, South Korea, Nov. 29, 2021 /PRNewswire/ -- On November 24, ST Pharm Co. Ltd., an API CDMO company in Republic of Korea, announced to build the second oligonucleotide manufacturing plant for an expansion of production facilities and t... |